Scopus BioPharma Announces Pricing of Initial Public Offering

Trading Set to Begin Wednesday, December 16th on Nasdaq Global Market

IPO Proceeds for Further Development of Company’s Novel, Targeted Immuno-Oncology Gene Therapy for Multiple Cancers

PR Newswire

NEW YORK, Dec. 15, 2020 /PRNewswire/ — Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the pricing of its initial public offering.

The company’s common stock is set to begin trading Wednesday, December 16, 2020 on the Nasdaq Global Market under the ticker symbol “SCPS”.

The company is offering 500,000 shares of common stock at a public offering price of $5.50 per share.

The Benchmark Company, LLC acted as Sole Bookrunning Manager and Joseph Gunnar & Co., LLC acted as Co-Manager for the offering.

Greenberg Traurig, LLP is acting as counsel to the company.  Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is acting as counsel to the underwriters.

An offering statement relating to the shares of common stock was filed with the U.S. Securities and Exchange Commission and became qualified on December 14, 2020. The offering is being made only by means of an offering circular, copies of which may be obtained, when available, by contacting: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected]; or Joseph Gunnar & Co., LLC, Attention: Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600 or by email at [email protected] The offering circular is also available on the U.S. Securities and Exchange Commission website at www.sec.gov.

Scopus BioPharma intends to use the proceeds of the offering principally to further development of the company’s lead drug candidate, a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions.  The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers.  The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.

Forward-Looking Statements

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company’s offering circular filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/scopus-biopharma-announces-pricing-of-initial-public-offering-301193596.html

SOURCE Scopus BioPharma Inc.

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds JOYY Inc. Investors of Important January 19 Deadline in First Filed Securities Class Action Commenced by the Firm – YY

PR Newswire

NEW YORK, Dec. 15, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of JOYY Inc. (NASDAQ: YY), between April 28, 2016 and November 18, 2020, inclusive (the “Class Period”), of the important January 19, 2021 lead plaintiff deadline in the first filed securities class action lawsuit commenced by the firm. The lawsuit seeks to recover damages for JOYY investors under the federal securities laws.

To join the JOYY class action, go to http://www.rosenlegal.com/cases-register-1988.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) the majority of users at any given time were bots; (3) JOYY utilized these bots to effect a roundtripping scheme that manufactured the false appearance of revenues; (4) JOYY overstated its cash reserves; (5) JOYY’s acquisition of Bigo was largely contrived to benefit corporate insiders; and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1988.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq. 
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827 
      [email protected]
      [email protected]
      [email protected] 
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-global-investor-counsel-reminds-joyy-inc-investors-of-important-january-19-deadline-in-first-filed-securities-class-action-commenced-by-the-firm—yy-301193595.html

SOURCE Rosen Law Firm, P.A.

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action – IPHA

PR Newswire

NEW YORK, Dec. 15, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, 2020, inclusive (the “Class Period”), of the important December 22, 2020 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit seeks to recover damages for Innate investors under the federal securities laws.

To join the Innate class action, go to http://www.rosenlegal.com/cases-register-1763.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Innate touted the results of its various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that it was eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose its renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, defendants’ statements about Innate’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 22, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1763.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-top-ranked-national-investor-attorneys-reminds-innate-pharma-sa-investors-of-important-december-22-deadline-in-securities-class-action–ipha-301193594.html

SOURCE Rosen Law Firm, P.A.

Viatris Inc. Recommends Caution on TRC Capital Corp.’s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer

PR Newswire

PITTSBURGH, Dec. 15, 2020 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited “mini-tender” offer by TRC Capital Corporation (“TRC”) to purchase up to 6,000,000 shares, or approximately 0.497 percent, of the outstanding common stock of Viatris at a price of $16.50 per share in cash. TRC’s offer price is approximately 4.84 percent less than the $17.34 closing price of Viatris’ common stock on December 11, 2020, the last trading day prior to the commencement of the mini-tender offer.

Viatris does not endorse TRC’s mini-tender offer and recommends that Viatris stockholders do not tender their shares in response to the offer because it is a mini-tender offer at a price below the market price for Viatris shares (as of the date Viatris received notice of the offer) and is subject to numerous conditions. According to TRC’s offer documents, Viatris stockholders who have already tendered their shares may withdraw their shares at any time prior to 12:01 a.m.New York City time, on Thursday, January 14, 2021, the expiration date set forth in the offer documents (unless extended or earlier terminated), by following the procedures described in the offer documents. Viatris urges stockholders to obtain current market quotes for their shares, to review the conditions to TRC’s mini-tender offer, to consult with their brokers or financial advisors and to exercise caution with respect to this mini-tender offer. Viatris is not associated with TRC, its mini-tender offer or the offer documentation.

TRC has made many similar mini-tender offers for shares of other companies. Mini-tender offers are designed to seek to acquire less than 5 percent of a company’s outstanding shares, thereby avoiding many disclosure and procedural requirements of the Securities and Exchange Commission (“SEC”) that apply to offers for more than 5 percent of a company’s outstanding shares. As a result, mini-tender offers do not provide investors with the same level of protections as provided by larger tender offers under United States federal securities laws.

The SEC has cautioned investors about these offers, noting that “some bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC’s Investor Tips regarding mini-tender offers may be found on the SEC’s website at www.sec.gov/investor/pubs/minitend.htm.

Viatris encourages brokers and dealers, as well as other market participants, to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosures at www.sec.gov/divisions/marketreg/minitenders/sia072401.htm and NASD’s Notice to Members 99-53 issued July 1999, regarding guidance to members forwarding mini-tender offers to their customers, which can be found at www.finra.org/web/groups/industry/@ip/@reg/@notice/documents/notices/p004221.pdf  Viatris requests that a copy of this press release be included with all distributions of materials relating to TRC’s mini-tender offer.

About Viatris

Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer’s Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viatris-inc-recommends-caution-on-trc-capital-corps-attempt-to-acquire-shares-at-a-significant-discount-via-mini-tender-offer-301193589.html

SOURCE Viatris Inc.

ROSEN, RESPECTED INVESTOR COUNSEL, Reminds K12 Inc. Investors of Important January 19 Deadline in Securities Class Action – LRN

PR Newswire

NEW YORK, Dec. 15, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of K12 Inc. (NYSE: LRN) between April 27, 2020 and September 18, 2020, inclusive (the “Class Period”), of the important January 19, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for K12 investors under the federal securities laws.

To join the K12 class action, go to http://www.rosenlegal.com/cases-register-1989.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; and (4) as a result, defendants lacked a reasonable basis for their positive statements about K12’s business, operations, and prospects. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1989.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-respected-investor-counsel-reminds-k12-inc-investors-of-important-january-19-deadline-in-securities-class-action–lrn-301193566.html

SOURCE Rosen Law Firm, P.A.

Orion to Acquire Centerra Gold’s 50% Interest in the Greenstone Gold Mines Partnership

THUNDER BAY, Ontario and TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) — PREMIER GOLD MINES LIMITED (“Premier”)(TSX:PG) (OTCPK: PIRGF) and CENTERRA GOLD INC. (“Centerra”) (TSX: CG) are pleased to announce that an affiliate of the Orion Mine Finance Group (“Orion”), has entered into an agreement (the “Purchase Agreement”) with Centerra and Premier pursuant to which Orion will acquire Centerra’s 50% interest in the Greenstone Gold Mines Partnership (“GGM”) for cash consideration of US$225 million (subject to certain adjustments) plus certain contingent payment obligations of approximately US$75 million (assuming a US$1,500 gold price), described below (the “Transaction”). Premier currently owns the other 50% of GGM.

GGM’s principal asset is the Hardrock Mine Project (“Hardrock” or the “Project”) located on the Trans-Canada Highway near Geraldton, Ontario, Canada and represents one of the most significant large-scale, permitted, mine development opportunities in North America.

Consideration under the Purchase Agreement is comprised of:

  • payment on closing from Orion to Centerra in the amount of approximately US$225 million (subject to certain adjustments); and
  • contingent payments due from Orion to Centerra, payable under certain circumstances, as follows (the “Contingent Payments”):

(i)  US$25 million in cash, payable within 24 months following a positive mine construction decision by GGM with respect to the Project;

(ii)  within 30 days of the Project achieving cumulative production of 250,000 ounces of refined gold, Orion shall deliver to Centerra, at Orion’s option, either: (A) 11,111 ounces of refined gold; (B) the cash equivalent value of 11,111 ounces of refined gold, based on the 20-day average spot gold price ending on the date immediately prior to the date of payment; or (C) a combination of refined gold and a cash equivalent of the shortfall ounces of refined gold;

(iii)  within 30 days of the Project achieving cumulative production of 500,000 ounces of refined gold, Orion shall deliver to Centerra at Orion’s option, either: (A) 11,111 ounces of refined gold; (B) the cash equivalent value of 11,111 ounces of refined gold, based on the 20-day average spot gold price ending on the date immediately prior to the date of payment; or (C) a combination of refined gold and a cash equivalent of the shortfall ounces of refined gold; and

(iv)  within 30 days of the Project achieving cumulative production of 700,000 ounces of refined gold, Orion shall deliver to Centerra at Orion’s option, either: (A) 11,111 ounces of refined gold; (B) the cash equivalent value of 11,111 ounces of refined gold, based on the 20-day average spot gold price ending on the date immediately prior to the date of payment; or (C) a combination of refined gold and a cash equivalent of the shortfall ounces of refined gold.

Under the terms of the Purchase Agreement, Premier and Centerra, through their respective affiliates, will cause GGM to provide a guarantee to Centerra in respect of the obligations of Orion to make the Contingent Payments, if any, and with respect to an early termination amount payable to Centerra upon early termination of the Purchase Agreement in certain circumstances, all of which will be secured by a fixed and floating charge and a continuing security interest in the GGM property. Following the closing of the Transaction, Orion intends to support a positive feasibility decision for the Hardrock project based on the feasibility study conducted in 2019.

The Transaction is subject to customary closing conditions for a transaction of this nature including the approval of the Toronto Stock Exchange (“TSX”) in respect of Premier with respect to the guarantee and the charge described above. It is also a condition of closing of the Transaction that all parties to the previously-announced Hardrock legal actions and related counterclaims, as well as Premier and Centerra, will provide a mutual release and consent dismissal in respect of the action and the related counterclaims. The Transaction is expected to close in January 2021.

“This transaction paves the way for the development of Premier’s flagship asset. We look forward to working with Orion, a long-standing supportive partner of Premier, in advancing the Hardrock Project on an expedited timeline”, stated Ewan Downie, President and CEO of Premier. “This new partnership will unlock the substantial value of one of North America’s most advanced, permitted and well-located, multi-million-ounce gold projects.”  

Istvan Zollei, portfolio manager at Orion, commented: “Orion looks forward to being a partner in turning the Hardrock Project into Ontario’s next prominent mine. After years of successful exploration and development work, we believe the Greenstone Project has the potential to grow into a large, long-lived gold mining operation with multiple deposits.”

Affiliates of Orion beneficially own or control approximately 13.9% of the outstanding common shares of Premier and, as such, Orion is considered a “related party” and an “insider” of Premier for the purposes of applicable securities laws and stock exchange rules. The agreement of Premier under the Purchase Agreement to cause GGM to provide the above-noted guarantee, and related charge, to Centerra may be considered a “related party transaction” between Premier, Orion and their respective affiliates for the purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Premier is relying on exemptions from the formal valuation and minority approval requirements otherwise mandated by MI 61-101, since at the time the “related party transaction” was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the “related party transaction”, insofar as it involves interested parties, exceeds 25 per cent of Premier’s market capitalization.

CIBC Capital Markets is acting as financial advisor to Premier with respect to the Transaction.

Premier Gold Mines Limited is a gold-producer and respected exploration and development company with a high-quality pipeline of precious metal projects in proven, accessible, and safe mining jurisdictions in Canada, the United States, and Mexico.

Centerra Gold Inc. is a Canadian-based gold mining company focused on operating, developing, exploring and acquiring gold properties in North America, Asia and other markets worldwide and is one of the largest Western-based gold producers in Central Asia. Centerra operates three mines, the Kumtor Mine in the Kyrgyz Republic, the Mount Milligan Mine in British Columbia, Canada and the Öksüt Mine in Turkey. Centerra’s shares trade on the TSX under the symbol CG. Centerra is based in Toronto, Ontario, Canada.

     
  For further information, please contact:

Ewan Downie, President & CEO
1.888.346.1390
In[email protected]
www.premiergoldmines.com

John W. Pearson, Vice President, Investor Relations
(416) 204-1953
[email protected]
www.centerragold.com

 
     

This Press Release contains certain information that may constitute “forward-looking information” under applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about the completion of the acquisition by Orion to acquire Centerra’s 50% interest in GGM, Premier’s ability to secure financing for its share of costs relating to Hardrock, strategic plans, including future operations, future work programs, capital expenditures, discovery and production of minerals, price of gold and currency exchange rates, mineral resource and mineral reserve estimates and corporate and technical objectives. Forward-looking information is necessarily based upon a number of assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information, including the risks inherent to the mining industry, adverse economic and market developments, the risks identified in Premier’s annual information form under the heading “Risk Factors” and the risks identified in Centerra’s 2020 annual information form under the heading “Risk Factors”. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Each of Premier and Centerra disclaim any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

A PDF accompanying this announcement is available at http://ml.globenewswire.com/Resource/Download/bf127a06-e225-4a1b-91fb-e030aca1bc4e 



Realtor.com® Acquires Avail

Online property management platform streamlines rental process for DIY landlords and tenants; acquisition advances realtor.com®’s rentals strategy

PR Newswire

SANTA CLARA, Calif., Dec. 15, 2020 /PRNewswire/ — Move, Inc., the operator of realtor.com®, a leading online destination for real estate services, announced today it has acquired Chicago-based Avail, a platform that improves the renting experience for do-it-yourself landlords and tenants with online tools, educational content, and world-class support. Move, Inc. is a subsidiary of News Corp.

The Avail acquisition helps realtor.com® further expand into the rental space with support for landlords and renters.

Residential rentals comprise a large market in the U.S.; according to an analysis of American Community Survey data from the U.S. Census Bureau, people spend more than $500 billion per year on rent in this country, and DIY landlords (landlords with 1-20 units, often in addition to a full-time job) own and manage about three quarters of all the rentals in the U.S.

The acquisition helps realtor.com® further expand into the rental space, extend its support for landlords, augment current rental listing content, grow its audience and build brand affinity and long-term relationships with renters.

The Avail online and mobile platform brings together the workflow tools that help independent landlords manage rental properties more easily and efficiently, almost all of which are free; more than 90 percent of landlords use the Avail free product, while some landlords upgrade for premium functionality and customizations. Landlords use the Avail platform to create and market rental listings, screen applicants, access state- and city-specific lease agreements, process payments and track maintenance requests. The platform also offers tools for renters, including easy ways to complete rental applications, sign leases, pay rent, submit maintenance requests and access related products and services like renters insurance.

“This acquisition is a key part of our strategy to make finding a home easier and more rewarding,” said David Doctorow, CEO of realtor.com®. “We believe that Avail is uniquely positioned to meet the needs of the DIY landlords and tenants in a large, growing and underserved market. By combining Avail’s rentals listing content and easy-to-use tools with realtor.com®‘s large audience, consumer experience platform and insights, we believe we can deliver more value to DIY landlords and tenants. I’m excited about what the tremendous team at Avail will add to the talented staff here at realtor.com®.”

Avail is experiencing incredible growth in the market despite the Coronavirus pandemic, as more landlords move their rental businesses online and consumers look for contactless rental opportunities, especially with online rent payments.

“We are excited about joining the team at realtor.com®, and see this acquisition as a tremendous opportunity for our customers,” said Avail CEO Ryan Coon. “Leveraging realtor.com®‘s industry expertise and scale will allow us to expand our platform capabilities and offerings so we can continue to deliver high-quality services, tools and education to even more landlords and tenants.” 

Coon, Avail co-founder Laurence Jankelow and the company’s 30+ person team will join Move, Inc. Terms of the acquisition were not made public.

About realtor.com®

Realtor.com® makes buying, selling, renting and living in homes easier and more rewarding for everyone. Realtor.com® pioneered the world of digital real estate more than 20 years ago, and today through its website and mobile apps is a trusted source for the information, tools and professional expertise that help people move confidently through every step of their home journey. Using proprietary data science and machine learning technology, realtor.com® pairs buyers and sellers with local agents in their market, helping take the guesswork out of buying and selling a home. For professionals, realtor.com® is a trusted provider of consumer connections and branding solutions that help them succeed in today’s on-demand world. Realtor.com® is operated by News Corp [Nasdaq: NWS, NWSA] [ASX: NWS, NWSLV] subsidiary Move, Inc. under a perpetual license from the National Association of REALTORS®. For more information, visit realtor.com®.

About Move, Inc.
Move, Inc., a subsidiary of News Corp [Nasdaq: NWS, NWSA] [ASX: NWS, NWSLV], operates a family of websites and mobile experiences for consumers and professionals, including realtor.com®. Move also offers software products and services to help real estate professionals serve their clients and grow their business, including ListHub™, the nation’s leading listings syndicator and centralized intelligence platform for the real estate industry; and Top Producer® Systems.

About Avail
Founded in 2012, Avail is the first and only online platform for independent landlords and tenants that provides the tools, education, and support to make renting easy. Landlords across the U.S. use Avail to advertise vacant units, request rental applications and credit reports, sign leases, and collect rent — all online. Learn more at www.avail.co.

Media Contact

Stephanie Singer


[email protected]
 

Cision View original content:http://www.prnewswire.com/news-releases/realtorcom-acquires-avail-301193515.html

SOURCE realtor.com

Alamo Group Announces CEO Retirement Plan

PR Newswire

SEGUIN, Texas, Dec. 15, 2020 /PRNewswire/ — Alamo Group Inc. (NYSE: ALG) announced today that Ron Robinson, the Company’s President and CEO, has informed the Board of Directors of his intention to retire preferably by mid-year 2021 and upon the appointment of his successor.  As part of its succession planning efforts, the Company’s Board of Directors has been preparing for such a transition and anticipates naming a new President and CEO as Mr. Robinson’s replacement within the next several months.  It is Mr. Robinson’s intention to continue on in his role as a member of the Company’s Board following his retirement as President and CEO.

In announcing his retirement, Mr. Robinson stated, “Having served as Alamo’s President and CEO for more than 21 years, I feel this is the right time for a change in leadership and for me to spend more time with my family.  It has been my absolute honor and privilege to lead such a great organization.  I have been fortunate to work alongside a very talented and dedicated group of people who I am sure will continue Alamo’s growth and future success.  I also have great confidence in the Board’s succession process given our focus on this important objective over the last few years.”

On behalf of the Board of Directors, Roderick R. Baty, Alamo Group’s Chairman said, “We would like to extend our gratitude to Ron for his extraordinary leadership during his 21 years of service as President and CEO. Under his guidance and strategic vision, Alamo Group has grown from a small domestically-focused company with 9 manufacturing locations, 9 distinct brands, 1,100 employees and sales of $177 million, to a multinational Company with 27 global manufacturing locations, more than 40 distinct brands, almost 4,000 employees and sales in excess of $1.1 billion. Corresponding net income and earnings per share grew from $6.1 million and $0.63 to $63.0 million and $5.33, respectively. Because of Ron’s stewardship, Alamo Group today is positioned as a financially sound and operationally strong company with significant opportunities for continued growth in the future. To our stakeholders – customers, dealers, employees, suppliers and shareholders, we wish to thank you for your support and acknowledge your contributions to the remarkable success of Alamo Group during Ron’s tenure.  While we will surely miss Ron’s leadership as CEO, we look forward to his ongoing participation as a member of the Board of Directors.  The Board has given careful consideration to succession planning and we are confident that our planning will result in an orderly and successful transition with ongoing steady leadership for Alamo Group.”

About Alamo Group
Alamo Group is a leader in the design, manufacture, distribution and service of high quality equipment for infrastructure maintenance, agriculture and other applications. Our products include truck and tractor mounted mowing and other vegetation maintenance equipment, street sweepers, snow removal equipment, excavators, vacuum trucks, other industrial equipment, agricultural implements, forestry equipment and related after-market parts and services. The Company, founded in 1969, has approximately 3,950 employees and operates 27 plants in North America, Europe, Australia and Brazil as of September 30, 2020.  The corporate offices of Alamo Group Inc. are located in Seguin, Texas.

Forward Looking Statements

This release contains forward-looking statements, including regarding the timing of the appointment of the Company’s new President and CEO, that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
 
Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company’s actual results in future periods to differ materially from forecasted results. Among those factors which could cause actual results to differ materially are the following: overall market demand, continuing impacts from the COVID-19 pandemic including more significant supply chain disruptions, further reductions in customer demand, sales and profitability declines, operational disruptions, full or partial facility closures, and other similar impacts, competition, weather, seasonality, currency-related issues, and other risk factors listed from time to time in the Company’s SEC reports.
 
The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Cision View original content:http://www.prnewswire.com/news-releases/alamo-group-announces-ceo-retirement-plan-301193554.html

SOURCE Alamo Group Inc.

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo. The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimer’s disease and type 2 diabetes. The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35. These differences were not statistically significant. Consistent with previous studies, azeliragon was generally well-tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups.

“We will continue to analyze the data to determine if there are potential benefits or future applications for azeliragon in Alzheimer’s, dementia or related indications that we or other interested parties may seek to pursue,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “On behalf of vTv Therapeutics, we would like to extend our most sincere and heartfelt gratitude to study participants, their families, physicians and caregivers for their commitment to this important study despite the challenging circumstances created by the COVID-19 pandemic.”

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s and related dementia, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), genetic mitochondrial diseases, and chronic kidney disease. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Contacts

Investors:

Corey Davis
LifeSci Advisors
[email protected]

or

Media:
Glenn Silver
Lazar FINN Partners
646-871-8485
[email protected] 

Source: vTv Therapeutics Inc. 



SHAREHOLDER ALERT: WeissLaw LLP Investigates Experience Investment Corp.

PR Newswire

NEW YORK, Dec. 15, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Experience Investment Corp. (“EXPC” or the “Company”) (NASDAQ: EXPC) in connection with the Company’s proposed merger with Blade Urban Air Mobility, Inc. (“Blade”), a privately-held technology-powered air mobility company.  Under the terms of the merger agreement, EXPC will acquire Blade through a reverse merger that will result in Blade becoming a public company traded on the NASDAQ.  The estimated post-transaction equity value of the combined company is approximately $825 million.


If you own EXPC shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


https://www.weisslawllp.com/expc/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether EXPC’s board acted in the best interest of EXPC’s public stockholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Blade, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to EXPC’s public stockholders. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-experience-investment-corp-301193568.html

SOURCE WeissLaw LLP